Harbin Medisan Stock Hits Day Low of CNY 13.77 Amid Price Pressure

Harbin Medisan Pharmaceutical Co., Ltd. experienced significant activity today, with the stock declining by 10.0% and reaching an intraday low of CNY 13.77. This performance stands in contrast to the China Shanghai Composite, which saw a slight increase of 0.04% on the same day. Over the past week, Harbin Medisan's stock has decreased by 1.08%, while its performance over the last month shows a notable increase of 37.7%. However, the company has faced challenges in the longer term, with a one-year performance decline of 8.87% compared to the Shanghai Composite's gain of 3.56%. Year-to-date, the stock has shown a positive return of 10.51%, contrasting with the broader index's decline of 1.6%. Financial metrics indicate that Harbin Medisan is grappling with poor management efficiency, reflected in a return on capital employed (ROCE) of 0% and a negative net worth. The company has reported losses for five consecutive quarters, with net sales and operating profit showing significant declines over the past five years. As a small-cap player in the pharmaceuticals and biotechnology sector, Harbin Medisan's market capitalization stands at CNY 2,465 million.